Neoepitopes of cancers: Looking back, looking ahead

Cancer Immunology Research

Volumn 3, Issue 9, 2015, Pages 969-977

  Srivastava, Pramod K ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR ANTIGEN;

ANTIGEN PRESENTATION; ARTICLE; CANCER GENETICS; CD4+ T LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; MAJOR HISTOCOMPATIBILITY COMPLEX; MALIGNANT NEOPLASTIC DISEASE; GENE; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; MUTATION; NEOPLASMS; PROCEDURES;

ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; GENES, MHC CLASS I; HUMANS; IMMUNOTHERAPY; MUTATION; NEOPLASMS;

EID: 84962016174     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0134     Document Type: Article

References (58)

1. Gross L. Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Res 1943;3:326-33.
2. Prehn RT, Main JM. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 1957;18:769-78.
3. Klein G, Sjorgen HO, Klein E, Hellstrom KE. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res 1960;20:1561-72
4. Basombrio MA. Search for common antigenicities among twenty-five sarcomas induced by methylcholanthrene. Cancer Res 1970;30:2458-62.
5. Srivastava PK, Old LJ. Individually distinct transplantation antigens of chemically induced mouse tumors. Immunol Today 1988;9:78-83.
6. Old LJ. Cancer immunology: the search for specificity-G. H. A. Clowes Memorial lecture. Cancer Res 1981;41:361-75.
7. Preuss KD, Zwick C, Bormann C, Neumann F, Pfreundschuh M. Analysis of the B-cell repertoire against antigens expressed by human neoplasms. Immunol Rev 2002;188:43-50.
8. Yuasa Y, Srivastava SK, Dunn CY, Rhim JS, Reddy EP, Aaronson SA. Acquisition of transforming properties by alternative point mutations within c-bas/has human proto-oncogene. Nature 1983;303:775-9.
9. Nasti TH, Rudemiller KJ, Cochran JB, Kim HK, Tsuruta Y, Fineberg NS, et al. Immunoprevention of chemical carcinogenesis through early recognition of oncogene mutations. J Immunol 2015;194:2683-95.
10. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med 1996;183:725-9.
11. Ramarathinam L, Sarma S, Maric M, Zhao M, Yang G, Chen L, et al. Multiple lineages of tumors express a common tumor antigen, P1A, but they are not cross-protected. J Immunol 1995;155:5323-9.
12. GSK MAGE-3 Vaccine Disappointing. Available from: http://www.melanoma.org/find-support/patient-community/mpip-melanoma-patientsinformationpage/gsk-mage-3-vaccine.
13. Update on phase III clinical trial of investigational MAGE-A3 antigenspecific cancer immunotherapeutic in non-small cell lung cancer. Available from: http://us.gsk.com/en-us/media/press-releases/2014/update-onphaseiii-clinical-trial-of-investigational-mage-a3-antigen-specific-cancerimmunotherapeuticin-non-small-cell-lung-cancer/
14. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008;358:2698-703.
15. Yuan J, Page DB, Ku GY, Li Y, Mu Z, Ariyan C, et al. Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy. Cancer Immun 2010;10:1.
16. Van der Bruggen P, Stroobant V, Vigneron N, Van den Eynde B. Tumor antigens resulting from mutations. 2013. Available from: http://cancerimmunity.org/peptide/mutations/.
17. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993;90:3539-43.
18. Hege KM, Jooss K, Pardoll D. GM-CSF gene-modified cancer cell immunotherapies: of mice and men. Int Rev Immunol 2006;25:321-52.
19. Srivastava PK. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 2002;20:395-425.
20. Suto R, Srivastava PK. Amechanismfor the specificimmunogenicity of heat shock protein-chaperoned peptides. Science 1995;269:1585-8.
21. Binder RJ, Han DK, Srivastava PK. CD91 is a receptor for heat shock protein gp96. Nat Immunol 2000;1:151-5.
22. Belli R, Testori A, Rivoltini L, Maio M, Andreola G, Sertoli MR, et al. Vaccination of metastatic melanoma patients with autologous Tumorderived heat shock protein gp96-peptide complexes. J Clin Oncol 2002;20:4169-80.
23. Testori A, Richards J, Whitman E, Mann B, Lutzky J, Camacho L, et al. Comparison of autologous tumor-derived heat shock protein gp96-peptide complex vaccine (vitespen) and physician's choice in a randomized phase 3 trial in patients with stage IV melanoma. J Clin Oncol 2008;26:955-62.
24. Erratum in: J Clin Oncol. Aug. 1;26:3819.
25. Wood CG, Escudier B, Lacombe L, Wentworth K, Yuh L, Gupta R, et al. A randomized Phase 3 trial comparing adjuvant therapy with autologous tumor-derived heat shock protein gp96 (vitespen) vs. observation in patients at high risk of recurrence of renal cell carcinoma. Lancet 2008;372:145-54.
26. Bloch O, Crane CA, Fuks Y, Kaur R, Aghi MK, Berger MS, et al. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol 2014;16:274-9.
27. Srivastava PK. Peptide-binding heat shock proteins in the endoplasmic reticulum: role in immune response to cancer and in antigen presentation. Adv Cancer Res 1993;62:153-77
28. Segal NH, Parsons DW, Peggs KS, Velculescu V, Kinzler KW, Vogelstein B, et al. Epitope landscapes in breast and colorectal cancer. Cancer Res 2008;68:889-92.
29. Srivastava N, Srivastava PK. Modeling the repertoire of true tumor-specific epitopes in a human cancer. PLoS One 2009;4:e6094.
30. Rajasagi M, Shukla SA, Fritsch EF, Keskin DB, DeLuca D, Carmona E, et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood 2014;124:453-62.
31. Al Seesi S, Duan F, Mandoiu II, Srivastava PK, Kueck A. Genomics-guided immunotherapy of human epithelial ovarian cancer. In: Rodriguez-Oquendo A, editor. Translational cardiometabolic genomic medicine. Oxford (UK): Elsevier, in press (2015).
32. Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A 2005;102:16013-8.
33. Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, Nelson BH, et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res 2014;24:743-50
34. Fritsch EF, Rajasagi M, Ott PA, Brusic V, Harcohen N, Wu CJ. HLA-binding properties in humans. Cancer Immunol Res 2014;2:522-9.
35. Sette A, Vitiello A, Reherman B, Fowler P, Nayersina R, Kast WM, et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 1994;153:5586-92.
36. Wentworth PA, Vitiello A, Sidney J, Keogh E, Chesnut RW, Grey H, et al. Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice. Eur J Immunol 1996;26:97-101.
37. Assarsson E, Sidney J, Oseroff C, Pasquetto V, Bui HH, Frahm N, et al. A quantitative analysis of the variables affecting the repertoire of T cell specificities recognized after vaccinia virus infection. J Immunol 2007;178:7890-901.
38. Castle JC, Kreiter S, Diekmann J, Löwer M, van de Roemer N, de Graaf J, et al. Exploiting the mutanome for tumor vaccination. Cancer Res 2012;72:1081-91.
39. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012;482:400-4.
40. Duan F, Duitama J, AlSeesi S, Ayres CM, Corcelli SA, Pawashe AP, et al. Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity. J Exp Med 2014;211:2231-48.
41. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014;515:577-81.
42. Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 2014;515:572-6.
43. van Rooij N, van Buuren MM, Philips D, Velds A, Toebes M, Heemskerk B, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 2013;31:e439-42.
44. Blum JS, Wearsch PA, Cresswell P. Pathways of antigen processing. Annu Rev Immunol 2013;31:443-73.
45. Stroobant V, Demotte N, Luiten RM, Leonhardt RM, Cresswell P, Bonehill A, et al. Inefficient exogenous loading of a tapasin-dependent peptide onto HLA-B-44:02 can be improved by acid treatment or fixation of target cells. Eur J Immunol 2012;42:1417-28.
46. Callahan MK, Wolchok JD, Allison JP. Anti-CTLA4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol 2010;37:473-84.
47. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189-99.
48. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015;372:2006-17.
49. Wang RF, Wang X, Atwood AC, Topalian SL, Rosenberg SA. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science 1999;284:1351-4.
50. Monach PA, Meredith SC, Siegel CT, Schreiber H. A unique tumor antigen produced by a single amino acid substitution. Immunity 1995;2:45-59.
51. Matsutake T, Srivastava PK. The immunoprotective MHC II epitope of a chemically-induced tumor harbors a unique mutation in a ribosomal protein. Proc Natl Acad Sci U S A 2001;98:3992-7.
52. Kreiter S, Vormehr M, van de Roemer N, Diken M, Löwer M, Diekmann J, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 2015;520:692-6.
53. O'Rawe J, Jiang T, Sun G, Wu Y, Wang W, Hu J, et al. Low concordance of multiple variant-calling pipelines: practical implications for exome and genome sequencing. Genome Med 2013;5:28.
54. Kim SY, Speed TP. Comparing somatic mutation-callers: beyond Venn diagrams. BMC Bioinformatics 2013;14:189.
55. Butros P, Ewing A, Ellrott K, Norman T, Dang K, Hu Y, et al. Global optimization of somatic variant identification in cancer genomes with a global community challenge. Nat Genet 2014;46:318-9.
56. Wang Y, Waters J, Leung ML, Unruh A, Roh W, Shi X, et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 2014;512:155-60.
57. Klinger M, Kong K, Moorhead M, Weng L, Zheng J, Faham M. Combining next-generation sequencing and immune assays: a novel method for identification of antigen-specific T cells. PLoS One 2013;8:e74231.
58. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science 2013 339:1546-58.